Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA)
•  Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA)
•  Biotech Advisory Panel Members for Hong Kong Stock Exchange (HKEX)
•  Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University
•  Former Deputy Director-General of the Department of Education, Science, Culture and Public Health in Legislative Affairs Office at State Council of China
•  Engaged in health and drug policy and legal studies for a long time, especially in optimizing the reform of drug review and approval system, medical insurance reimbursement system and making policies for pharmaceutical innovation in China
Founding Managing Director, Northern Light Venture Capital
Mr. Feng Deng founded Northern Light Venture Capital (NLVC) in 2005. He currently manages over US$ 4.5 billion with 5 US$ funds and 5 RMB funds. He has led and backed nearly 200 companies, focusing on 4 main sectors: TMT (technology, media and telecom), clean technology, healthcare and consumer. The portfolio companies that Feng invested and manages include APUS, ThunderSoft, Macrosan, Meituan, Baihe, LineKong, ChineseAll, GigaDevice, BGI, China Music, LianLian, Burning Rock Biotech, Hillstone Networks, Spreadtrum, CITIC Pharma, Aerohive Networks, etc.
Prior to NLVC, Feng was a co-founder of NetScreen Technologies, which went public on NASDAQ and was later acquired by Juniper Networks in 2004 for US$ 4.2 billion. Feng is recipient of Ernst & Young Entrepreneur of the Year (2002) and CRN Innovator of the Year (2003) awards. He has extensive technical and managerial experiences in computer, communication and data networking industries.
Feng holds BS and MS degrees in electrical engineering from Tsinghua University, a MS degree in computer engineering from the University of Southern California, and a MBA degree from the Wharton School, University of Pennsylvania. He also holds numerous patents of invention in computer system architecture and IC design.
Northern Light Venture Capital (NLVC) is a leading China-focused venture capital firm targeting early stage opportunities of innovation and disruptive technology. Since founded by Feng Deng in 2005, Northern Light has backed over 200 ventures in TMT, healthcare and advanced technology. Leveraging significant investing and entrepreneurial expertise in both China and the United States, the NLVC team looks to support entrepreneurs with groundbreaking ideas and exceptional vision to develop lasting ventures that positively impact society.
Executive Director & Editor of New, VenturesBioCentury Inc
Mr. Berlin leads business development and relationship management in China and Asia. At BioCentury, Josh created, launched and manages the BioCentury-BayHelix China Healthcare Summit. This annual VIP event in Shanghai is organized by BioCentury and BayHelix in collaboration with McKinsey & Co. and celebrated its 5th anniversary in 2018.
Mr. Berlin is also a founding organizer of the China Healthcare Dinner for C-Suite Executives, a cross-border networking event held in San Francisco during JPM week since 2012. Prior to joining BioCentury in 2014, Josh for seven years created and led the emerging markets group for Elsevier Business Intelligence (now Informa plc), including PharmAsia News and the annual PharmAsia Summit.
Managing Partner, Biotrack Capital
Kevin (Penghui) Chen is Managing Partner of Biotrack Capital. Prior to his current role, he was partner at Sequoia Capital, responsible for healthcare investment. Before Sequoia Capital, Mr. Chen served as head and managing director of Everbright Healthcare. He led investment in many leading healthcare companies in China including BGI, Amcare, Betta Pharmaceuticals Inc, JIDA Pharmaceuticals Inc, Yuwell Medical, Zai Lab, Medtrum Medical, STP, Bai Yang Pharmaceuticals, Forerunner Medical, Guahao, etc. Before Everbright, he worked at ShangPharma, a leading China CRO company, first as COO & CFO between 2008 and 2010, and later as President in 2011. He took the company public at NYSE in 2010. Prior to ShangPharma, Mr. Chen was a vice president at CITIC Capital, responsible for healthcare and consumer industry. Before CITIC Capital, he held executive positions at BD & Corporate Investment at fortune 500 companies. Mr. Chen also worked as research scientist at Ligand Pharmaceuticals (Nasdaq: LGND) in San Diego, California.
Mr. Chen holds a bachelor’s degree in chemistry from Nanjing University, a master’s degree in medicinal chemistry from Tulane University and an MBA from Kellogg School of Management, Northwestern University.
Venture Partner, LYFE Capital
Keting Chu is Venture Partner of Lyfe Capital that is focused on healthcare VC investments in the US and China. Keting is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development and venture investment.
Prior to joining Lyfe Capital, Dr. Chu was venture partner at Apple Tree Partners. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS), and is responsible for venture philanthropy. Prior to LLS, Keting co-founded, as head of RnD or CEO, four biotech companies including Five Prime Therapeutics, Bio 3 , DigitAB and Mission therapeutics. Before that, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation and she was responsible for the R&D pipeline of biologic.
Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF).
Managing Director, DigitalDX Ventures
Ted Driscoll is Managing Director at a new venture fund, DigitalDx Ventures, whose focus is on Diagnostics in a Big-Data and Personalized Medicine World. Previously he was a Partner at Decheng Capital, and a Partner at Claremont Creek Ventures leading Digital Healthcare. He led the first investment in Natera (IPOed 2015), AssureX (acquired by Myriad Genetics for $410M) and GeneWeave (acquired by Roche for $425M). Prior to entering venture capital, he was an early leader/founder of five startups. His first startup, International Imaging Systems, built the first Digital Subtractive Angiography machines. He then led the team at Identix that pioneered the first digital fingerprint recognition, now used in the iPhone. Identix IPOed in 1984. He then joined Diasonics where he led the team that created the world’s first MRI scanners. He was then named Division President of a spinoff from Diasonics named Focus Surgery that pioneered noninvasive HIFU ablation surgery. This company IPOed in 1992. His last startup was Be Here Technologies, a 360degree imaging company, which was purchased by and incorporated into Google Streetview.
President and COO, Zai Lab
Tao Fu has been our President & Chief Operating Officer since September 2018. Prior to joining Zai Lab, he worked with Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company's corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company, Becton Dickinson, etc.
Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).
Of Counsel, Regulatory and, Compliance
Joshua Gruenspecht is Of Counsel in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he advises clients in the telecommunications, technology, media, and defense sectors on transactional, regulatory, and litigation matters. He has negotiated
security agreements, information sharing agreements, and network and physical security plans and policies with CFIUS, DSS, the FCC, and various other federal agencies. He currently represents the National Venture Capital Association (NVCA) in connection with the rulemaking that will implement CFIUS reform legislation.
Managing Director, Fosun Group
Mr. Han is a Managing Director at Fosun Healthcare Holdings. He is based in New York and is responsible for Fosun Group’s overseas investments in the healthcare sector. Prior to joining Fosun, he was the Global Corporate Development Director at Henry Schein and has over 12 years of experiences in mergers, acquisitions, divestures, and other types of investments. He graduated from Shandong University and received Master’s Degree from Michigan State University and an MBA from the Wharton School of Business.
Fosun Group is one of the largest investment conglomerates headquartered in shanghai China. It has over $60 billion under management. Fosun was founded in 1992 in Shanghai. Fosun International (00656.HK) was listed on the Main Board of the Hong Kong Stock Exchange on July 16, 2007.
Over the last two decades, Fosun has evolved from an entrepreneurial start-up into a leading investment group taking roots in China with a global foothold. Fosun has been actively implementing its investment model of “Combining China’s Growth Momentum with Global Resources” and adhering to its “value-investing” discipline, aspiring to becoming a world-class investment group underpinned by the twin drivers of “insurance-oriented integrated financial capability” and “global industrial integration capability taking roots in China”.
Bosun Hau
Managing Director & Partner, Sailing Capital
Bosun has 15 years of healthcare and finance experience, primarily as a healthcare and TMT investor in both private and publicly-listed companies in the US, EU and China. Prior to joining Sailing Capital, Bosun was a Partner at MVM Life Science Partners in Boston and London. He also has experience at JP Morgan in New York, McKinsey & Company in Singapore, Eli Lilly & Company and S.R. One, GlaxoSmithKline’s Corporate Venture Group. Bosun is or has been a Board Director or Observer for several leading public and private biotechnology, medical technology, specialty pharmaceutical and food technology companies.
Bosun holds an MBA from the Wharton School and a Masters of Biotechnology from Johns Hopkins University. He also is a triple-bachelor degree recipient from the University of Arizona. Bosun serves on the Board of Overseers at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard University Medical School.
Michael Fu
Managing Director and Head of Everbright Healthcare Fund, China Everbright Holding
Mr. Fu is the Managing Director and Head of Everbright Healthcare Fund who is fully in charge of the Healthcare Fund. Fu has over 13 years of experiences in investment, covering companies in early stage, growth stage and merger and acquisition stages. Mr. Fu worked as the head of healthcare investment departments at Hillhouse Capital, TPG Capital, FountainVest Partners etc.
Mr. Fu led the privatization of Wuxi AppTec and the investments of Daopei hospital, Amcare, We Doctor, Junshi Bioscience, Qiming Medical, CITIC Pharmaceutical etc. Fu also has 8 years of experience in the operation of a healthcare company. He was the National Sales and Marketing Manager of Sanjiu Pharmaceutical Co. Ltd., leading a 500 person sales and marketing team. He was responsible for exclusive agency business with multinational pharmaceutical companies and the acquisition of Wuxi Pharmaceutical.
Mr. Fu received his MBA from the University of British Columbia in Canada and Bachelor's Degree of Economics and International Finance from East China Normal University in Shanghai. He is a CFA charter holder as well.
Xiaofang Hu
CD Capital, Managing Director
Xiaofang has 20+ years experience in healthcare research and investment. Prior to joining CD Capital, Xiaofang was Executive Director at Tasly Pharma Investment and Managing Director at Huajin Jintian Capital. She also held the leadership position at Sinoipro IP Management and Technology Transfer Co. Before joining the industry, she was a professor and Principle Investigator at Shanghai Jiao Tong University. She received her B.S. and M.S. from Nanjing University and attained her PhD from Shanghai Jiao Tong University, Postdoctor training at Harvard University.
Managing Partner, KPCB China; Managing Partner, Panacea Venture
James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. James has made more than 15 investments in China since 2007. Before coming to KPCB China, James was a managing partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
James is Chairman of Board at Kindstar Global, JHL Biotech and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, EntreMed, XW Laboratory and Omni Pharmaceuticals.
James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. He was born in Taipei, Taiwan.
Partner, Corporate
James (Jim) Jensen is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on corporate and securities law. Jim has 18 years of legal experience. During that span he has represented corporate, angel, and venture capital firms in investment transactions in the U.S. and China. He also represented start-up and emerging growth companies at all stages of development. His clients include companies across a diverse range of industries, including digital media, internet, medical devices, mobile, security, and software. Jim is also a technology entrepreneur who formed and ran several e-commerce and other internet companies.
Partner, Illumina Ventures
Alexis Ji brings 12 years of experience in research and venture investment in the genomics and pharmaceutical industries. At Illumina Ventures, Ms. Ji focuses on investing in early-stage genomics technology platforms and applications in life science tools, diagnostics, therapeutics, and digital health.
Prior to Illumina Ventures, Ms. Ji was a principal at WuXi Apptec Corporate Venture Fund and then WuXi Healthcare Ventures, a U.S.-China cross-border life science venture capital firm. She was instrumental in investments in Twist Bioscience, 23andme, Juno Therapeutics, Syros Pharmaceuticals, Unity Biotechnology, Vivace Therapeutics, Medeor Therapeutics, Ideaya Therapeutics, and Lumo Bodytech. Before joining WuXi, Ms. Ji was a venture investment consultant at ARCH Venture Partners.
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides most of our capital and access to the expertise and vision of the world's leading genomics solutions provider.
Managing Partner, Qiming Venture Partners
Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China. which currently manages over USD 4 billion in assets and investment in over 280 companies.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Laboratories (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology, New Horizon Bio and Berry Oncology. She also oversees Qiming’s investments in Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics and Jacobio.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, member of Committee on Hong Kong Innovation and Technology Development and Re-Industrialization and advisor of Our Hong Kong Foundation. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.
Founded in 2006, Qiming is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen and Hong Kong. In 2017, Qiming raised its first US fund, and set up Qiming’s US offices in Seattle, Boston and Palo Alto. Currently Qiming manages seven US Dollar funds and five RMB funds with US$4 billion assets under management. Since our debut, we have backed over 280 young, fast-growing and innovative companies across China in the internet and consumer ("Intersumer"), healthcare, information technology and clean technology sectors. Over 50 of them are already listed on NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange or achieved exit through M&A. There are also nearly 20 portfolio companies that have been recognized as unicorns in the industry.
Partner and Managing Director, Ally Bridge Group
Dr. Bin Li is a Partner and Managing Director of Ally Bridge Group as well as CEO & CIO of Ally Bridge LB Healthcare Fund. Dr. Li is involved in deal sourcing and post-investment value add to the ABG portfolio. Dr. Li joined ABG from Morgan Stanley where he was a Managing Director and the Head of Greater China Healthcare Research. Dr. Li was consistently ranked as the top analyst in Asia healthcare industry by various investor polls, including No.1 Asia healthcare analyst by the Institutional Investor for seven consecutive years (2009-2015), Wall Street Journal, Greenwich and Asia Money. Dr. Li brings both life science and finance expertise to ABG as he was educated as a biochemist and had worked at Merck Research Lab as a scientist before receiving an MBA and joining the equity research industry, where he spent 16 years as a healthcare equity research analyst at Merrill Lynch in the US before joining Morgan Stanley in Asia.
Dr. Li received his PhD in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Dr. Li brings a wealth of industry knowledge, analytics, expertise and network to the ABG team.
Ally Bridge Group, founded and led by Frank Yu (previously at Goldman Sachs and Och-Ziff Capital), is a global healthcare-focused investment firm. ABG and its affiliates manage over US$2 billion in healthcare assets in China, the U.S., and Europe, from medtech to biopharmaceuticals. ABG focuses on investing in some of the world's most innovative medicines and leading high-impact transactions. In 2015, ABG initiated, led and completed the landmark US$3.3 billion NYSE take-private of Wuxi Pharmatech. ABG has expertise in cementing strategic partnerships between emerging healthcare companies and industry leaders, and across different geographies, particularly between the U.S., China and Europe.
Director, Corporate Finance, Haitong International Capital Limited
Ms. Liu has extensive experience in the Hong Kong capital market and has successfully completed the IPO projects of companies in the healthcare industry in Hong Kong, such as Genscript Biotech, BBI Life Sciences, Austar Lifesciences, and IPO projects of other industries, such as 7Road, Galaxy Securities, China Everbright Bank, Harbin Bank, Sunshine 100, and Shenzhen State Microelectronics etc. Ms. Liu has also completed refinancing projects for a number of Hong Kong listed companies, such as Shanghai Pharmaceuticals placement.
Prior to joining Haitong International, Ms. Liu worked in an investment company in China, focusing on medical and biotechnology industry, responsible for preproject evaluation and analysis, as well as investor relations.
Ms. Liu holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard University and has many years of experience in academic research in China and abroad.
Founding & Managing Partner, Redhill Capital, Venture Partner, Sequoia Capital China
Cherry Lu is Founding & Managing Partner of Redhill Capital, Venture Partner of Sequoia Capital China. Cherry joined Sequoia Capital China in 2005 and founded Redhill Capital in early 2018. She led the investments for companies including Jafron Biomedical (300529), Snibe Diagnostic, ARMO(Nasdaq ARMO), WinnerMedical, Iraychina, Xtalpi and others, many of which have been developed into the leading enterprises in their respective fields.
Cherry earned The best VB100 investors of the year in 2017, Forbes 2018 Top 25 the best female venture capitalist in China. She is the mentor of CKGSB FMBA program, and co-founder of Pine Club.
She graduated from Tongji Medical College of Huazhong University of Science and Technology in 1996,Graduated as an MBA from the Chinese University of Hong Kong in 2004 and EMB from CKGSB in 2017.
Partner, Lilly Asia Ventures
Dr. Hongbo Lu is a partner at Lilly Asia Ventures, a healthcare-focused investment firm with over USD$1.2 billion AUM. She has over 15 years of investment and operational experience in healthcare industry, including her tenures at OrbiMed, Piper Jaffray & Co. and life science start-up Zyomyx. Prior to Lilly Asia, Dr. Lu was with OrbiMed Advisors, serving as its Managing Director in Asia, responsible for over $500m public equity investment portfolio in emerging markets. She also led a few private equity investments in OrbiMed. Dr. Lu served as board of directors of private and public companies.
Dr. Lu received a Ph.D. in Bio Engineering from the University of Washington, an MBA from the Haas School of Business at the University of California, Berkeley, and graduated with honor from Tsinghua University in China.
Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. LAV Biosciences Fund IV with a total fund size of $450 million was closed in May 2017.
Associate Professor of Biological Engineering and Electrical Engineering and Computer Science, MIT
Timothy Lu is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, Tango Therapeutics, Corvium, and Engine Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, the 2018 Xconomy Scientific Founder of the Year, among others.
Partner, Sequoia Capital China
Before joining Sequoia Capital China, Mr. Lu served as a healthcare partner at Shenzhen Cowin Venture Capital Investment Limited, focusing on healthcare investment. During his seven years in Cowin Venture Capital, he led over 30 healthcare investments, including: BGI (SZSE:300676), Betta Pharmaceuticals (SZSE:300558), Jingfeng Pharmaceuticals (SZSE:000908), Konruns Pharmaceuticals (listing applications submitted), Chipscreen, Innovent, Zhongankang (acquired and gone private), etc. Prior to Co-Win Venture Capital, Mr. Lu had 15 years of experience in pharmaceutical sales and marketing. He worked in China Resource Sanjiu for almost ten years.
Mr. Lu received a bachelor’s degree in biochemistry engineering from Zhejiang University and an MBA degree from Tsinghua University.
Sequoia team helps daring founders build legendary companies. In partnering with Sequoia, companies benefit from our unmatched community and the lessons we have learned over 45 years working with Apple, Cisco, Oracle, Google, Alibaba, Airbnb and JD.com among many others. As “The Entrepreneurs Behind The Entrepreneurs”, Sequoia China focuses on four sectors: TMT, healthcare, consumer/service, and industrial technology. Over the past 12 years we have had the privilege of working with more than 300 companies in China, including Alibaba, AutoNavi, Beta Pharma, BGI, Deppon Logistics, Dianping, Didi, DJI, Ganji.com, Hero Entertainment, JD.com, Jumei, Meituan, Meilishuo, Momo, Noah, Ourpalm, Qihoo 360, Sina.com, SINNET, Snibe Diagnostic, Toutiao, VanceInfo, VIPshop, Wanda Cinemas, Wego Group, Yuwell Medical, ZTO Express. Sequoia has operations in China, India, and the United States.
Hai Mi
Founding Managing Partner, Panacea Ventures
Prior to founding Panacea Ventures, Dr. Hai Mi joined Kleiner Perkins Caufield & Byers China as a partner in 2015 and focuses on the firm’s life sciences practice.
Prior to joining KPCB China, Dr. Mi was a partner DT Capital responsible for investment in life science, healthcare and other related fields. Dr. Mi was the venture partner of SB China Venture Capital (SBCVC) and his investment transactions include BGI, SyMap Medical and Precise Light. Dr. Mi was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi PharmaTech (NYSE: WX) in Shanghai where he played an important role in NYSE listing, investor relations, and the acquisition of AppTec in US. He also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee, and he participated in the privatization of Chemspec. Earlier Dr. Mi was a research scientist at Pfizer in US.
Dr. Mi obtained a Ph.D. in organic chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in material science from Fudan University in Shanghai.
Managing Director, Head of Healthcare, Private Equity, VMS Investment Group
Andrew Ng is a Managing Director of VMS Group and is responsible for its healthcare investment practice. Prior to VMS Group, Andrew was the Head of China Healthcare Equity Research at Barclays Capital. Before that, he was an investment banker at Barclays focusing on cross-border healthcare M&A and a management consultant at ZS Associate in the United States advising global big pharma on sales & marketing strategy and operations.
Andrew received an MBA from INSEAD and holds a MEng degree and a B.S. degree in Operations Research & Engineering from Cornell University.
VMS Group is a multi-strategies investment group based in Hong Kong with diversified businesses covering proprietary investments, structured finance, asset management, securities brokerage and corporate finance advisory. The Group, with AUM around US$ 3 billion, makes private investments in private / public equity as well as special situation investments including distressed assets, acquisitions of controlling equities, collateralized loans and bonds.
Partner, Decheng Capital
Dr. Pliam is trained as a cell biologist and orthopedic surgeon, and has worked within, and as an advisor to, biopharmaceutical and medical technology companies. He is a founder of Guided Delivery Systems, a medical device company developing a minimally invasive technology for treatment of mitral valve regurgitation, and a founder of Pharmagenesis, a natural products pharmaceutical company. As an independent consultant and as managing director of a boutique investment banking firm, he has advised life science companies and investors (including Biomet, Devax, Hanwha Pharmaceutical, Marubeni Group, Micrus Endovascular, and Triage Medical) on financing transactions and strategy. He is an inventor with patents in medical devices and biopharmaceuticals. Dr. Pliam serves on the boards of directors of Nevro Corporation (NYSE: NVRO) and a former member of the board of IDev Technologies (acquired by Abbott Laboratories).
He holds an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco. Dr. Pliam completed his surgical training at UCSF and Stanford University. He completed his undergraduate degree in German literature from the University of California, Berkeley, and studied at Georg August Universitaet in Goettingen.
Decheng Capital is a leading investment firm that provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence.
Chairman, BayHelix, Managing Partner, Serica Partners
Dr. Shi focuses on investing in diagnostics and medical devices in China as General Partner of Serica Partners. Among Serica's portfolio, he serves as CEO of Nuprobe and Vice Chairman of Anchor Dx. Previously he was Founding President Asia Pacific of QIAGEN, and held senior positions at Aura Partners, Bridge Pharmaceuticals, Genospectra, and A. M. Pappas & Associates. He was also a faculty member at National University of Singapore, School of Medicine and a cancer research scientist at Merck & Co.
Victor is Chairman of Bayhelix Group, a global association of Chinese life science business executives, Deputy Secretary-General of Chinese In-Vitro Diagnostics Industry Association, Vice Chairman of the Advanced Medical Technology Association (AdvaMed) China board, and serves on the Hong Kong Stock Exchange Biotech Advisory Committee.
Partner, Corporate
Barry Taylor is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati with 35 years of experience as a corporate and securities attorney and investment professional. From 2000 to 2010, Barry was a managing director in the technology, media, and telecom group of Warburg Pincus, a global private equity firm. He served as the head of the firm's Silicon Valley office from 2000 to 2008. While at Warburg, Barry worked on investments in the United States, India, and China, and represented the firm on the boards of six portfolio companies.
Partner, OrbiMed
Jonathan Wang, Ph.D., is a Partner and Senior Managing Director on the Asia team, focused on Greater China. With approximately 30 years of healthcare and life sciences experience, spanning investment, entrepreneurship and research, he co-founded OrbiMed Asia. He has been named one of the top 10 healthcare investors in China (ChinaVenture). Previously, he held leadership positions at Burrill and WI Harper. He is a HKEX Biotech Advisory Panel member and is a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.
Under the supervision of Eric Kandel, a Nobel Laureate, Dr. Wang obtained a Ph.D. in Molecular Neurobiology from Columbia University. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.
OrbiMed has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $14 billion across public and private company investments worldwide.
Partner, Intellectual Property
Dr. Karen Wong is a life sciences IP partner at Wilson Sonsini Goodrich & Rosati. Her practice includes freedom-to-operate and due-diligence studies, patent preparation and prosecution, opinion work, litigation strategy, and technology licensing. Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.
Wei Wu
Healthcare Investment Director, BOE Ventures
Dr. Wu is the Healthcare Investment Director of BOE Ventures, the corporate venture arm of BOE Technology Group. She’s an advisor of Berkeley SkyDeck. She is also the Co-Chair of Biotech/Genomics investment committee of Life Science Angels. Her investment areas cover genomics, research tool, diagnostics, pharmaceuticals including new modalities (gene therapy/cell therapy/bioelectronic medicine), and health-tech.
Managing Director, Hillhouse Capital
Dr. Vincent Xiang is a managing director at Hillhouse Capital. Prior to that, he was a partner at 6 Dimensions Capital. He has over 20 years of experience in the life sciences industries in the U.S. and China. From 2013 to 2016, Dr. Xiang was Managing Director and Head of international investments & business development at Humanwell Healthcare Group (600079.SH), which has $1.3B/year in revenue in 2015. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, scouting first in class assets. From 2004 to 2012, Dr. Xiang was Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies at all stages. Previously, he was Vice President of business development at Genyous, a US biotech start-up. He was also Director of venture investment at Acacia Research, Associate at BioAdvance (a healthcare Angel fund), and Irvington Fellow at Skirball Center and licensed his patented technology to Millennium Pharmaceutical for royalty payments. Dr. Xiang began his career at Sinopharm in China.
Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.
Hillhouse Capital is the leading Private Equity firm in Asia founded by Zhang Lei. It has closed a new $10.6 billion fund, the largest-ever capital raise by a private-equity firm in Asia. Current total Asset Under Management is over $50 billion.
President of Fosun Healthcare Holdings; Chairman of Overseas Healthcare Service Group; Chief Representative of Fosun U.S. office Fosun International - Healthcare Holdings
Kevin Xie is the President of Fosun Healthcare Holdings, Chairman of Overseas Healthcare Service Group and Chief Representative of Fosun U.S. office. In his current role, Mr. Xie is responsible for Fosun Group’s global healthcare investments in both primary and public market. Prior to joining Fosun in 2015, Mr. Xie co-founded Locust Walk Capital, a global healthcare hedge fund. Before that, He served as the healthcare sector head at Scopia Capital, a multi-billion USD market neutral long-short equity hedge fund. He was a portfolio manager and managing director at Great Point Partners, a premier healthcare hedge fund / private equity fund.
Mr. Xie holds an MBA from The Wharton School, a PhD in Chemistry from City University of New York, and a BS in Material Engineering from Tianjin University
Stella Xu
Managing Director, Quan Capital
Dr. Stella Xu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. Prior to Quan, Dr. Xu was a core member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases areas, and VP/Site Head of Roche Innovation Center Shanghai. From 2012-2017, she led the integrated research & early development site of ~200 scientists, successfully delivered a world-class innovative pipeline from Discovery to global Clinical Development in 3 years, and pioneered novel development strategies in China. Prior to her R&D leadership role, Dr. Xu had extensive global business development and licensing experiences across deal types and disease areas. After establishing the Roche Partnering office in Shanghai in 2008, she managed business development activities in APAC (ex-Japan). She also led global due diligence transaction activities and managed key alliances from research collaboration to marketed products in Roche Partnering US for years. Dr. Xu joined Roche from McKinsey US where she led management consulting engagements in diverse healthcare sectors and functional areas from R&D to commercialization. Earlier in her career, Dr. Xu worked in biotech R&D in oncology & inflammation.
Dr. Xu received her Ph.D. in Immunology from Northwestern University, and B.S. in Biophysics from Peking University.
Dr. Xu currently serves on the Board of ARMO BioSciences, Centrexion Therapeutics and Tempest Therapeutics.
Guo-Liang Yu
Venture Partner, OrbiMed
Guo-Liang Yu, Ph.D., is a Venture Partner with OrbiMed. Dr. Yu is currently the Executive Chairman of Crown Biosicence Inc., a leading oncology platform company in China. Previously he was Chairman and CEO of Epitomics Inc., an antibody company acquired by Abcam for $170 million.  Dr. Yu was a Senior V.P. at Mendel Biotechnology Inc. and a Senior Scientist at Human Genome Sciences Inc., where he contributed to the discovery of BLys, the target for lupus antibody drug Benlysta.
Dr. Yu obtained his Ph.D. from the University of California Berkeley and was trained at Harvard Medical School as a postdoctoral fellow. He has co-authored 40 peer-reviewed scientific articles and is also a co-inventor of more than 200 patents.
Dr. Yu serves on the boards of several professional organizations including BayHelix, National Foundation of Cancer Research and the Chinese Biopharmaceutical Association.
Partner, IDG Capital
Jianbin Zhang is involved in investments in variety of sectors for the medical care industry, including medicine, diagnostic reagents and medical instruments. Jianbin also has expertise in new drug developments, medicine sales channels, medicine marketing and enterprise management. He received an MBA from Cheung Kong Graduate School and holds a bachelor's degree in Engineering from Nanjing University of Chemical Engineering. Jianbin is also a Licensed Pharmacist.
IDG Capital is a leading investment firm, focused on developing extraordinary companies through our expertise in private equity and venture capital, as well as real estate. Founded in 1992, we were the first firm to bring foreign venture capital into China. Today we work with private equity and venture capital fund managers, investment advisors and business entities from around the world. Our limited partners include many internationally reputable investors, including governments/sovereign wealth funds, pension funds, institutional investors, major charities, university endowments, family offices and business luminaries.
Founder and Managing Partner, Fusion Fund
Lu Zhang is the Founder and Managing Partner of Fusion Fund. Fusion Fund supports early-stage entrepreneurs who are looking to build globally disruptive companies using innovative technologies to drive systemic change. Lu leads the management team consisting of seasonal investors, distinguished entrepreneurs and top tier scientists. Recently, Lu is selected as 2018 Young Global Leader by the World Economic Forum (Davos). Before this, she also got selected as Silicon Valley Women of Influence 2018 and Top 10 all America Chinese Youth. In 2017, she was awarded as the Forbes US 30 under 30 & Featured Honoree of VC category and also awarded as the Forbes Asia 30 under 30 of Finance category. In the same year, Lu was selected as the Town & Country 50 Modern Swans Influencer, representing top female entrepreneurs and influencers in the U.S.
Prior to starting Fusion Fund, Lu was a Venture Partner at Fenox Venture Capital. She was also the Founder and CEO of a medical device company focused on non-invasive technology for the early diagnosis of Type II diabetes (acquired in 2012). Lu is active in the entrepreneur and investor communities providing mentorship and serves as an advisor to programs like Microsoft AC, Singularity University, StartX at Stanford, and Youth Council of Future Forum. Lu received her M.S. in Materials Science and Engineering from Stanford University and holds several patents.
Tong Zhang
Managing Director, C-Bridge Capital
Tong Zhang joins as Managing Director in the New York City office, bringing with him more than 20 years of healthcare experience spanning corporate, investment and research roles. Most recently Zhang was Head of Corporate Business Development at Wuxi AppTec in Shanghai, where he led strategic partnerships for biopharmaceuticals, medical devices, diagnostics and genomics. Prior to that he oversaw executive partnership programs as part of the leadership teams at MSD China, Merck & Co. and EKR Therapeutics. He also spent the earlier part of his career in investment banking at ESP Equity Partners and Credit Suisse.
Founding Partner, LYFE Capital
James Zhao has a total of 21 years of experience in the healthcare industry, of which, prior to founding LYFE Capital, he was at Vivo Capital for 8 years. Initially trained in clinical medicine, he attained his MBA from Olin school of Business. James is based out of LYFE Capital's Shanghai and Menlo Park offices.
Founded in 2015, LYFE Capital is a dedicated healthcare fund that has successfully raised $720 million and is currently deploying out of our 2017 vintage year, $420 million fund. LYFE Capital is actively seeking healthcare companies with exceptional management teams and vision in the Sino-American markets, focusing on growth and innovation stages. LYFE Capital’s investment focus spans biopharmaceuticals; medical devices; life science tools and diagnostics; animal health; and healthcare services. LYFE Capital works closely with its portfolio companies to support their needs by not only providing capital but with active support in global expansion, global partnerships, market planning, and talent acquisition. LYFE doesn’t see our portfolio companies as just investments, but rather partners.
Partner, Tasly International Capital
Richard Zhao has 20 years of experience in M&A, Business Development and Sales & Marketing Management on both global and regional levels. Prior to Tasly Capital, Mr. Zhao was Chief Investment Officer and SVP, Medical Technology Division of Fosun Pharma. Prior to joining Fosun Pharma, Mr. Zhao held various executive positions at Bayer Healthcare and Philips Healthcare, driving international business growth and expansion. He was one of the early explorers in the 1990’s to introduce multinational companies to China, and has helped many multinational companies enter and operate in China through Shanghai Free Trade Zone.
Mr. Zhao holds an MBA degree from CEIBS and received executive education (CPD) from the Wharton School of University of Pennsylvania.
Tasly Capital is an investment arm of Tasly Holding Group. Tasly is a leading Chinese pharmaceutical company based in the city of Tianjin. It was established in 1994 and is notably producing traditional Chinese medicines. It has a turnover of 4 billion US dollars, 10,000 employees and is listed on the Shanghai Stock Exchange.
Partner, CD Capital
Ruilin has 20+ years’ experience in management in healthcare industry. Prior to joining CD Capital, Ruilin was the Vice President and General Manager of Commercial Operations for Greater China at Illumina. He also held several leadership positions at Thermo Fisher, including China head of Corporate Marketing and Commercial Operations. Prior to Thermo Fisher, Ruilin held roles as Vice President of Finance at OrbusNeich and Vice President of Business Development at Microport Medical (Group) Co.
Ruilin received his doctorate in medical engineering and medical physics from the Harvard-MIT Division of Health Sciences and Technology, a Masters of Business Administration from the Wharton School at the University of Pennsylvania, a master's in electrical engineering and computer science from Massachusetts Institute of Technology, and a bachelor's in biomedical engineering from Xi'an Jiaotong University.
CD Capital, founded in 2013, is A boutique healthcare PE fund specialized in MedTech and Life Science. It has a team grouped by medical doctor, engineers and scientists. CD Capital is backed by well-known LP funds, family offices, and university endowments. The current AUM is around $667 million USD.
Partner, Pagoda Capital Partners
Dr. Pei Zhou has more than 15 years of research and investment experience in the healthcare industry.  Prior to Pagoda Investment, Dr. Zhou serves as a Senior Associate of China Everbright Limited Healthcare Investment Fund, and is responsible for sourcing, evaluating and the execution of equity investments in pharmaceutical, med tech and healthcare services sub-sectors.  Previously, he worked for CITICPE, one of the largest private equity funds ($7B AUM currently) in China and has successfully invested several deals including: 3SBio, Biosensors, and BeiGene.  He received his PhD in Biology (Genetics and Cell Biology) from Dartmouth College in 2011, and received his ME and BE in Biochemical Engineering from Tianjin University in 2004 and 2001.